NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced disclosure of additional data from its ongoing clinical trial (NCT03168139) testing NOX-A12 alone (part 1) and subsequently in combination with Keytruda® (part 2) in metastatic, microsatellite stable pancreatic and colorectal cancer patients.
The additional data includes the comparison of baseline tumor biopsies to those taken after two weeks of NOX-A12 monotherapy for all patients for whom matched tumor biopsies were available and analyzed at the time of publication. These data show that markers consistent with a Th1 like immune responses were seen in multiple patients in response to NOX-A12 therapy, in addition to changed levels of CXCL12 in tumors confirming penetration of NOX-A12. Data on changes in cell infiltration looking at a pan-T-cell (CD3) and a Myeloid cell (CD11b) marker will also be provided. The Company confirms that the safety profile of NOX-A12 continued to be consistent with prior experience where its administration was generally safe and well tolerated as monotherapy and in combination with approved anti-cancer agents considering the patient population.
The presentation is available on NOXXON’s website.